DGX News 59.48 Quest Diagnostics Inc (DGX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Quest Diagnostics Inc (DGX) 59.48 $DGX

11.3% Return Seen to Date on SmarTrend Quest Diagnostics Call (DGX)
Comtex SmarTrend(R) - Wed Apr 16, 11:04AM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE GX) on March 11th, 2014 at $53.79. In approximately 1 month, Quest Diagnostics has returned 11.31% as of today's recent price of $59.87.

Equities to Watch in the Health Care Sector -- Research on Novadaq Technologies, Quest Diagnostics, Cooper Cos, and AcelRx Pharma
PR Newswire - Tue Apr 15, 11:56AM CDT
The trading session on Monday, April 14, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,173.24, up 0.91% and the NASDAQ Composite closed at 4,022.69, up 0.57%. The S&P 500 finished the session 0.82% higher at 1,830.61. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 648.05, up 0.51%, while the same has declined 3.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Novadaq Technologies Inc. (NASDAQ: NVDQ), Quest Diagnostics Inc. (NYSE: DGX), The Cooper Cos Inc. (NYSE: COO) and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). Free technical research on NVDQ, DGX, COO and ACRX can be downloaded upon signing up at:

The Zacks Analyst Blog Highlights: Quest Diagnostics, Vornado Realty Trust, Equity One, Simon Property Group and Duke Realty
PR Newswire - Tue Apr 15, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Quest Diagnostics Inc. (NYSE GX-Free Report), Vornado Realty Trust (NYSE:VNO-Free Report), Equity One Inc. (NYSE:EQY-Free Report), Simon Property Group Inc. (NYSE:SPG-Free Report) andDuke Realty Corp. (NYSE RE-Free Report).

Addus HomeCare (PAL) Crumbles: Stock Drops 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 8:15AM CDT
Addus HomeCare’s shares fell over 5% yesterday, breaking its one-month volatile trading range

RadNet (RDNT) in Focus: Stock Adds 8.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:37AM CDT
RadNet, Inc. was a big mover last session, as the company saw its shares rise more than 8% on the day.

Clinical Laboratory Services Market 2013-2018: Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles
M2 - Tue Apr 15, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d98zpd/clinical) has announced the addition of the "Clinical Laboratory Services - Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles" report to their offering. The Clinical Laboratory Services estimates the market at $99.1 billion for 2013, up 1.3% from the estimated value in 2008 of $92.7 billion. Faced with daunting reimbursement cuts and other challenges, the world market for clinical laboratory services grew just over one percent in the past five year. The report notes that while there are a number of drivers for this market: aging populations, a growing incidence of chronic diseases, increasing emphasis on diagnosis and disease monitoring, and a growth in advanced testing technologies and practices. However, there are also a number of inhibitors to growth such as the growing emphasis to reduce health costs and uncertain economic conditions, and these are dampening growth. In the United States, the U.S. Congress ultimately has the responsibility to adjust the Medicare fee schedule according to economic factors, including controlling costs, monitoring utilization, and ensuring adequate delivery of health care services. The passing of the Patient Protection and Affordable Care Act generated a number of provisions on laboratory fee schedules, mostly in the direction of reductions. These reductions were effective starting 2011 and will continue to be adjusted through 2015. Medicare has slashed reimbursement amounts for many common tests such as Vitamin B12, triglycerides and glucose nearly six percent between 2009 and 2013. Some tests, such as total iron or aluminum tests have been cut 19% and 30% respectively during that period. Bio-Reference Laboratories, Quest, Lab Corp, Myriad, and Spectra are among the leaders in the industry. Quest Diagnostics and LabCorp have advantages in the market due to the wide exposure, large number of locations, and greater financial positions. Smaller, independent laboratories may find it difficult to keep up with the fast changing industry largely due to limited financial abilities to invest in new technologies and testing services. Some laboratories, such as Bio-Reference Labs have found success in operating on a regional basis while companies such as Myriad Genetics and Genomic Health remain competitive by focusing on more specialized genetic-based testing. Key Topics Covered: 1. Executive Summary 2. Industry Overview 3. CLIA Laboratory Registration, Laboratories By Type 4. Leading Market Participants 5. Market Trends And Summary Companies Mentioned - Bio-Reference Laboratories - Clarient, Inc. - DaVita - Genomic Health - Genoptix, Inc. - Genzyme Corporation - Laboratory Corporation of America (LabCorp) - Quest Diagnostics, Inc. - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/d98zpd/clinical

Quest Diagnostics Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 4:32PM CDT
Adjusted earnings per share of Quest Diagnostic came in at $1.03, beating the Zacks Consensus Estimate of 94 cents by 9.6%, and exceeding the company's prior-year earnings by 2%.

Laboratory Service Providers Should Profit From This New Revenue Source
Bob Chandler, The Motley Fool - Motley Fool - Mon Apr 14, 1:30PM CDT
Medical testing leaders such as Laboratory Corporation of America and Quest Diagnostics have disappointed investors with little to no sales and profit growth over the past couple years. Sluggish demand and collapsing prices have smothered...

Priority Reviews, Preliminary Earnings Releases, Clinical Trials Results, and Launch of Website - Analyst Notes on Gilead, Pfizer, Intuitive Surgical, Alkermes and Quest
PR Newswire - Fri Apr 11, 9:14AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Intuitive Surgical, Inc. (NASDAQ: ISRG), Alkermes plc (NASDAQ: ALKS) and Quest Diagnostics Inc. (NYSE: DGX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/989-100free.

Gentiva Health Slumps: GTIV Falls 6.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:33AM CDT
Shares of Gentiva Health fell over 6% on the day. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $8.5 to $9.5 in the past one-month time frame. This home health services provider company has seen a flat track record when it comes to current year estimate revisions.

Global In-Vitro Toxicology/Toxicity Testing (Cell Culture, HTS, Omics) Market 2014-2018
M2 - Wed Apr 09, 9:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59cs9d/invitro) has announced the addition of the "In-Vitro Toxicology/ Toxicity Testing Market by Industry, Technology, Applications & Method - Global Forecast to 2018" report to their offering. The global market of in-vitro toxicology testing is subdivided into industry, technology, method, application and geography. On the basis of industry, the market is further segmented into diagnostics, pharmaceuticals, chemicals, cosmetics, and food. Diagnostics is further categorized into sample and type. The largest market share was captured by the pharmaceutical industry, whereas cosmetics industry was the fastest growing industry with a double digit CAGR. The prime factor contributing to the growth of pharmaceutical industry has been the attention towards the detection of toxicity during earlier stages of development. On the basis of technology, the global market of in vitro toxicology testing is divided into cell culture, high throughput screening, cellular imaging, and omics technologies. Cell culture technology will witness the maximum growth rate in the coming years. The methods considered for the study are cellular assays, biochemical assays, ex vivo and in silico. Cellular assays market is estimated to grow at a double digit CAGR during the forecast period (2013-2018). Cellular assays can predict the biological properties of potential drug compounds. These assays can also detect and measure cell viability, functionality and growth. Under the applications, the market is segmented into systemic toxicity, dermal toxicity, ocular toxicity, endocrine disruption (reproductive & developmental toxicity) and others. Systemic toxicity testing was the largest segment in 2013. The increasing focus on detection of toxicity in earlier stages of development is leading to persistent requirement for human cell-based in vitro models for cardiotoxicity and liver toxicity testing which are the major reasons for drug attrition. Europe commanded the largest share of the global market in 2013. This is attributed to the support provided by the European government for anti-animal testing laws. The government has further put ban on the production and sale of all animal tested cosmetics across the continent. The market will be driven by increasing acceptance of in-vitro toxicology testing methods as alternatives to in vivo toxicology testing. The new technologies in the in vitro testing market help in investigating the adverse effects of environmental agents in a more mechanistic and time saving manner. Organizations such as REACH foresee that more results of in vitro and in silico methods will be included in risk assessment which will promote the use of in vitro methods for toxicology testing. Scope Industry - Diagnostic - Pharmaceutical - Cosmetics - Chemical Technology - Cell Culture - HTS - Omics Applications - Systemic - Dermal - Ocular Method - Cellular Assay - Ex vivo - In Silico Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - By Industry - By Technology - By Application - By Method - Geographic Analysis - Competitive Landscape - Company Profiles - Agilent Technologies, Inc. - Alere, Inc. - Bio-Rad Laboratories, Inc. - Bioreliance, Inc. - Catalent - Charles River Laboratories International, Inc. - Covance, Inc. - Cyprotex - Eurofins Scientific - GE Healthcare - Life Technologies Corporation - Quest Diagnostics Visit http://www.researchandmarkets.com/research/59cs9d/invitro

CombiMatrix Names Trilochan Sahoo, M.D., Director of Cytogenetics
GlobeNewswire - Wed Apr 09, 5:00AM CDT
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that Trilochan Sahoo, M.D. FACMG, has recently joined the Company as Director of Cytogenetics. Dr. Sahoo will report to Wes Tyson, M.D., Chief Medical Officer of CombiMatrix.

Healthcare Companies Report Recognitions, Schedules, and Stock Movements - Analyst Notes on WellPoint, Quest Diagnostics, LabCorp, Covance, and Masimo
PR Newswire - Tue Apr 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Quest Diagnostics Inc. (NYSE: DGX), Laboratory Corp. of America Holdings (NYSE: LH), Covance Inc. (NYSE: CVD), and Masimo Corporation (NASDAQ: MASI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Patients Nationwide Now Have Direct Access to Lab Test Results through Quest Diagnostics
PR Newswire - Mon Apr 07, 11:46AM CDT
For the first time, Americans nationwide can directly access their personal laboratory data through Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. Quest Diagnostics provides diagnostic information services to about 30% of American adults each year.

Walgreen, Water Street Sign Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 2:20PM CDT
Walgreen has signed a definitive agreement with Water Street.

Better Buy: Laboratory Corp Vs. Quest Diagnostics
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 9:58PM CDT
Lab services may not be the first investment idea you consider when thinking about warm weather plays, but maybe it should be. Major lab services plays Laboratory Corp and Quest Diagnostics both remind investors in their annual reports that...

Quest Diagnostics To Release First Quarter 2014 Financial Results On April 24
PR Newswire - Thu Apr 03, 4:19PM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2014 results on Thursday, April 24, 2014, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.

Myriad Genetics Jumps on Medicare Decision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 1:50PM CDT
Shares of Myriad Genetics gained 11.47% on yesterday's close.

When Harsh Medicare Cuts Are Cause for Celebration
David Williamson, The Motley Fool - Motley Fool - Wed Apr 02, 6:53PM CDT
Another of today's winners in the health-care space is Myriad Genetics , up 11% today after Medicare reimbursement cuts were announced. Though the cuts were harsh, they were lower than the market had been fearing, and Myriad came out on top as a...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fervo’s 46% Slide Puts Geothermal Claims Under Fire

Updated Category News Views 162

A 46% haircut from an IPO price has a way of stripping the paint off a growth story. Fervo Energy closed at $14.33 after the October 6 report cited in Hagens Berman’s announcement, well below its $27 IPO price from last May. That does not prove the report is right. It does mean NASDAQ:FRVO investors are staring at questions that go straight to the economic spine of...

Continue Reading
Five SEAL Medal of Honor Signatures, One Charity Lot

Updated Category News Views 74

A single rifle can carry a staggering amount of meaning when the names on it belong to all five living U.S. Navy SEAL Medal of Honor recipients. Rock Island Auction Company plans to offer that one-of-a-kind custom precision rifle during its December 4–6, 2026 Premier Firearms Auction, and the financial arrangement is unusually clean: 100% of proceeds are slated for the...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
Lieda Shadwick’s Career Education Work Earns 2026 Honor

Updated Category News Views 76

Twenty-six years in classrooms is not the sort of accomplishment that needs fireworks to carry weight. Lieda A. Shadwick’s recognition as The Inner Circle’s 2026 Educator of the Year points to a career built around a stubbornly important idea: students need more than academic vocabulary if they are going to navigate work, leadership, and business with any confidence....

Continue Reading
Cloud Optical Demand Is Running Ahead of Supply in 2026

Updated Category News Views 15

Fiber capacity has become the awkward bottleneck nobody can wish away. Dell’Oro Group says the optical transport equipment market expanded 24% year over year in the third quarter of 2026, with large North American cloud providers doing the heavy lifting. More pointedly, optical vendor revenue tied to those cloud customers jumped 75%. That is not a gentle improvement in...

Continue Reading
PBS Holiday Special Bets on Apollo 8, Music and Unity

Updated Category News Views 54

A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...

Continue Reading
SKINformed Bets on Skin Longevity Over Quick Fixes

Updated Category News Views 95

Wrinkle panic has been a very profitable racket for a long time, and SKINformed is trying to sidestep it. The physician-founded skincare brand is planting its flag on “SKINgevity,” a term it uses to describe long-term skin health rather than a frantic hunt for an overnight rewind. That is a sensible read on where beauty consumers appear to be headed: less appetite for...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 65

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 47

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
Danaher and Microsoft Put AI Into the Lab Stack Early

Updated Category News Views 6

Laboratory AI gets interesting only when it reaches the hardware bench, and Danaher is taking a serious swing at that ugly, complicated job with Microsoft. The Nov. 20 partnership is not just another chatbot bolted onto a dashboard. It is aimed at building a common agentic platform that can help instruments interpret scientific intent, guide setup, control hardware within...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Trends: The Effects of Inflation on Stock Futures

Updated Category News Views 87

Understanding Stock Market Movements Amid Inflation The stock market is always changing, and the way inflation data interacts with labor statistics often shapes its future direction. Recently, U.S. stock futures saw a slight uptick as investors digested fresh figures, weighing how these will influence upcoming decisions regarding interest rate cuts. Current Market...

Continue Reading
SMBC Nikko America Achieves Primary Dealer Status with Fed

Updated Category News Views 557

SMBC Nikko America Achieves Primary Dealer Designation SMBC Nikko Securities America, Inc., commonly referred to as SMBC Nikko America, has recently been honored with the designation of primary dealer by the Federal Reserve Bank of New York. This prestigious status is not only a recognition of the firm’s robust capabilities but also signals significant opportunities for...

Continue Reading
USD and Global Currency Trends Amid Upcoming Economic Events

Updated Category News Views 272

Currency Market Insights for the Upcoming Week As economic indicators and central bank policies loom large, the focus shifts to the financial markets where currencies react to evolving data. The US dollar has shown resilience recently, making a notable comeback. This rebound is attributed to a combination of safe haven flows and exceptionally positive data releases. Fed...

Continue Reading
Transforming $100 into Wealth: American Tower's Success Story

Updated Category News Views 152

The Wealth Generated by American Tower's Growth American Tower (NYSE: AMT) has exhibited exceptional performance over the past two decades, consistently outshining the market with a remarkable annual return of 10.05%. As of now, this powerhouse company boasts a market capitalization of approximately $83 billion, signaling its robust position in the telecommunications...

Continue Reading
Calcea: The Future of Calcium with Plant-Based Solutions

Updated Category News Views 258

Revolutionizing Calcium Supplements with Calcea Calcium is recognized as the most abundant mineral in the human body, yet many of the supplements available today are derived from ground-up rocks – materials that aren't aligned with the nutritional needs of the human body. With consumers increasingly prioritizing cleaner and more effective supplements, the calcium market...

Continue Reading